Myeloproliferative Neoplasms | Specialty

Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms

May 30th 2015

Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.

Pacritinib Shows Promise for Spleen Reduction in Myelofibrosis

March 10th 2015

Pacritinib, a JAK2/FLT3 multikinase inhibitor, significantly reduced spleen volume for patients with myeloproliferative neoplasms when compared to non-JAK2 inhibitors.

Incyte Medical Officer Elaborates on Ruxolitinib Benefit for Polycythemia Vera

January 29th 2015

For additional insight on the published RESPONSE data and the use of ruxolitnib to treat polycythemia vera, we reached out to Richard Levy, MD, executive vice president and chief drug development and medical officer at Incyte, the company that co-manufactures ruxolitinib with Novartis.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

August 5th 2014

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

Ruxolitinib Outperforms Standard Therapy in Polycythemia Vera

July 24th 2014

In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.

Dr. Komrokji on Pacritinib for the Treatment of Myelofibrosis

April 21st 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

Ruxolitinib Improves Outcomes for Patients With Polycythemia Vera in Phase III Study

March 7th 2014

Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options

Dr. Tefferi on the Toxicity Profile of Imetelstat

January 23rd 2014

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.

Telomerase Inhibitor Imetelstat Shows Promise in Myelofibrosis

December 10th 2013

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

Updates in Hematology Oncology

September 13th 2013

Updates on new dosing strategies, formulations, and other information on treatments for patients with non-Hodgkin lymphoma, indolent B-cell non-Hodgkin lymphoma, and myelofibrosis.

JAK2 Inhibitor Shows Promise in Myelofibrosis

May 8th 2013

The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.

Dr. Ruben Mesa on Late-Stage Trials in Myelofibrosis

April 15th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

Dr. Silver on Hydroxyurea and Interferon in MPNs

April 3rd 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.

Dr. Mesa on Long-Term Data From the COMFORT Trials

March 25th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Study Confirms Treatment Target in Patients With Polycythemia Vera

March 6th 2013

Patients with the rare form of blood cancer polycythemia vera whose hematocrit levels hover between 45% and 50% have a four-fold higher incidence of thrombotic complications.

Dr. Richard T. Silver Discusses the Use of Interferons in MPNs

March 1st 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.